Tokai Pushes Edge With Three-Pronged Attack on Prostate Cancer

(Page 2 of 2)

trace amounts of the hormone. Another is by blocking an enzyme called CYP17 that allows the body to make small amounts of testosterone in adrenal glands, which can happen even while standard hormone-blocking drugs are essentially instructing the brain not to produce any testosterone, Montgomery says. The other way Tokai fights the cancer is by reducing the number of hormone receptors in prostate cancer tumors, essentially so they can’t vacuum up any testosterone in the body, Montgomery says.

One potential side effect to watch for will be if the drug turns off a lot of the normal ability of the adrenal system, Montgomery says. “What if you can’t make cortisol?” he asked, noting that would be a problem since cortisol is involved in the body’s natural response to stress and anxiety.

But there’s plenty of enthusiasm in the medical community for what Tokai is doing, Montgomery says. The Phase I/II clinical trial is being conducted at leading cancer centers like the University of Washington/Fred Hutchinson Cancer Research Center, the Sidney Kimmel Comprehensive Cancer Center, UCLA, Dana-Farber Cancer Institute, Roswell Park Cancer Institute, and others. “There’s excitement that this could be the beginning of what proves to be a very effective drug, perhaps the likes of which we haven’t seen before,” Montgomery says.

The technology for what became Tokai has its roots in the medicinal chemistry lab of Angela Brodie at the University of Maryland School of Medicine in Baltimore, says Tokai’s Harrison. Venture capitalists have been encouraged by the triple-threat mechanism of action of the company’s drug in animal tests, and they will hope to see at least a few anecdotal cases early on of the lower PSA scores that are a good sign that a patient is improving, Harrison says.

If all goes well, Tokai may have some preliminary evidence from its first clinical trial to present this June at the American Society of Clinical Oncology, Harrison says.

Single PageCurrently on Page: 1 2 previous page

By posting a comment, you agree to our terms and conditions.

3 responses to “Tokai Pushes Edge With Three-Pronged Attack on Prostate Cancer”

  1. John Arnold says:

    As someone who is going on four years into what is still a hormone responsive case of advanced prostate cancer, I am very pleased that this sort of creativity is being applied to “what comes next?” for men like me who will face that day and question some day. The more tools there are in the took kit, the better the chances of getting a right fit for any individual’s unique situation.
    Thanks, Tokai, the researchers who dreamed this stuff up and figured out the chemistry, and the men who will be participating in the clinical trials that will test it. Your work on this is very much appreciated!